Approaches for trigger-inducible viral transgene regulation in gene-based tissue engineering.
Recent advances in mammalian transgene expression dosing have resulted in a portfolio of mutually compatible systems that can adjust therapeutic transgene levels in response to antibiotics, hormone analogues, quorum-sensing messengers and secondary metabolites. The molecular merger of trigger-inducible expression technology with the latest generation of virus-derived transduction systems has enabled unmatched clinical interventions to shape desired therapeutic cell and tissue phenotypes for the treatment of complex human diseases.
Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Hoenggerberg, CH-8093 Zurich.
Wilfried
W
Weber
Martin
M
Fussenegger
D000818:Animals; D005786:Gene Expression Regulation; D005814:Genes, Viral; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000627:therapeutic use*; D006801:Humans; D012107:Research Design; D023822:Tissue Engineering / Q000379:methods / Q000639:trends; D019076:Transgenes / Q000235:genetics*